Ginsberg Gary, Hattis Dale, Russ Abel, Sonawane Babasaheb
Connecticut Department of Public Health, Hartford, Connecticut 06134, USA.
J Toxicol Environ Health A. 2004 Feb 27;67(4):297-329. doi: 10.1080/15287390490273550.
Children's risks can differ from those in adults for numerous reasons, one being differences in the pharmacokinetic handling of chemicals. Immature metabolism and a variety of other factors in neonates can affect chemical disposition and clearance. These factors can be incorporated into physiologically based pharmacokinetic (PBPK) models that simulate the fate of environmental toxicants in both children and adults. PBPK models are most informative when supported by empirical data, but typically pediatric pharmacokinetic data for toxicants are not available. In contrast, pharmacokinetic data in children are readily available for therapeutic drugs. The current analysis utilizes data for caffeine and theophylline, closely related xanthines that are both cytochrome P-450 (CYP) 1A2 substrates, in developing PBPK models for neonates and adults. Model development involved scale-up of in vitro metabolic parameters to whole liver and adjusting metabolic function for the ontological pattern of CYP1A2 and other CYPs. Model runs were able to simulate the large differences in half-life and clearance between neonates and adults. Further, the models were able to reproduce the faster metabolic clearance of theophylline relative to caffeine in neonates. This differential between xanthines was found to be due primarily to an extra metabolic pathway available to theophylline, back-methylation to caffeine, that is not available to caffeine itself. This pathway is not observed in adults exemplifying the importance of secondary or novel routes of metabolism in the immature liver. Greater CYP2E1 metabolism of theophylline relative to caffeine in neonates also occurs. Neonatal PBPK models developed for these drugs may be adapted to other CYP1A2 substrates (e.g., arylamine toxicants). A stepwise approach for modeling environmental toxicants in children is proposed.
儿童面临的风险可能因多种原因而异于成人,其中一个原因是化学物质在药代动力学处理方面的差异。新生儿不成熟的代谢以及多种其他因素会影响化学物质的处置和清除。这些因素可纳入基于生理的药代动力学(PBPK)模型,该模型可模拟环境毒物在儿童和成人中的命运。当有经验数据支持时,PBPK模型提供的信息最为丰富,但通常没有毒物的儿科药代动力学数据。相比之下,儿童治疗药物的药代动力学数据很容易获得。当前的分析利用咖啡因和茶碱的数据来开发新生儿和成人的PBPK模型,咖啡因和茶碱是密切相关的黄嘌呤,均为细胞色素P - 450(CYP)1A2底物。模型开发涉及将体外代谢参数放大至整个肝脏,并根据CYP1A2和其他细胞色素P450的本体模式调整代谢功能。模型运行能够模拟新生儿和成人在半衰期和清除率方面的巨大差异。此外,这些模型能够重现新生儿中茶碱相对于咖啡因更快的代谢清除率。发现黄嘌呤之间的这种差异主要是由于茶碱存在一条额外的代谢途径,即甲基化回咖啡因,而咖啡因本身没有这条途径。在成人中未观察到这条途径,这体现了未成熟肝脏中次要或新代谢途径的重要性。新生儿中茶碱相对于咖啡因的CYP2E1代谢也更强。为这些药物开发的新生儿PBPK模型可能适用于其他CYP1A2底物(如芳胺毒物)。本文提出了一种为儿童环境毒物建模的逐步方法。